New analysis shows CAR-T drug wildly overpriced
Novartis' taxpayer-funded drug Kymriah is overpriced by $315,000 per treatment
Novartis' taxpayer-funded drug Kymriah is overpriced by $315,000 per treatment
Patients For Affordable Drugs is the only independent national patient organization focused exclusively on achieving policy changes to lower the price of prescription drugs.
